Mike Tyson Unveils New Cannabis Brand in New York

Business by 2FIRSTS.ai
Jan.22.2024
Mike Tyson Unveils New Cannabis Brand in New York
Hundreds of Mike Tyson fans lined up outside a New York pharmacy to support his new marijuana business venture.

According to a recent report by The New York Times, hundreds of followers of Mike Tyson, one of the greatest boxers of all time, lined up at a pharmacy in New York over the weekend in hopes of getting a chance to meet him and show support for his latest business venture: selling marijuana in his home state.

 

According to reports, 57-year-old Tyson has recently launched the Tyson 2.0 brand, emerging as one of the most notable newcomers in the New York cannabis industry. As the legalization of cannabis gradually spreads across the United States, actors, athletes, and musicians have been profiting from the marijuana industry through product lines and sponsorship contracts for over a decade. However, the trend has only recently started to gain momentum in New York. Tyson is seeking to test his fame and become a prominent figure in what is projected to become the world's largest and most competitive market.

 

The evaluations of cannabis brands backed by celebrities are mixed. While their sales often surpass those of traditional brands, they cannot compete with the biggest brand that sells millions of dollars worth of cannabis every month.

 

According to data from Headset, a specialized cannabis data company, out of the top 30 bestselling brands in California, the largest market in the United States, only 9 of them are owned or endorsed by celebrities. These include Tyson 2.0, actor Seth Rogen's Houseplant, and musician Carlos Santana's Mirayo.

 

One of the company analysts, Mitchell Laferla, noted that the ultimate driving factor for consumers in emerging markets like New York is value, and this is precisely where celebrity-endorsed brands face difficulties.

 

Consumers who spend lavishly are now seeking the most powerful features at the lowest prices, while the quality of celebrity brands varies, often commanding higher prices. In California, a bag of 3.5 grams typically sells for around $23.14, whereas Tyson 2.0 is priced at approximately $28.44, representing a 23% difference.

 

Lafra states that the success of Tyson 2.0 can be attributed to the way Tyson interacts with its clients and their companies, its proactive expansion into new markets such as New York and Maryland, and the quality of its products.

 

"Your name may entice someone to give it a try," he said. "But it's your brand and product quality that are the factors that keep people coming back."

 

Yuvraj Singh, the CEO of Long Island Strain Stars, has stated that customers have returned to purchase more cannabis from Tyson Foods. On the first day of the launch of their Tyson 2.0 flower line, their customers bought a total of $30,000 worth of cannabis products, making the cannabis series one of the top five best-selling products in the store.

 

According to reports, he described its effect as a highly pleasurable and refreshing sensation.

 

Coss Marte, co-owner and CEO of Conbud, has stated that their pharmacy has also attracted more customers to make purchases, selling $10,000 worth of Tyson 2.0 within an hour, which is equivalent to the pharmacy's typical daily sales.

 

Former boxing champion Mike Tyson has emphasized the therapeutic effects of marijuana in his transformation from an arrogant athlete to a disciplined businessman. In an interview, he revealed that less than a decade ago, he was penniless and struggling with a cocaine addiction. Today, he is the owner of one of the most successful celebrity marijuana brands in the country.

 

Tyson stated that his goal is to solidify his legacy as a pioneer of cannabis. "This is more important to me than making money," he declared.

 

Tyson was born into a financially disadvantaged family in Brooklyn and later discovered his boxing talent at a reform school in the north. He quickly became a teenage sensation and eventually won 50 professional matches, most of which were victories by knockout.

 

However, his reputation has been tarnished due to his antics, such as biting Hollyfield's ear, as well as his legal troubles, including a three-year prison sentence for a rape case that he still denies. In 2014, he revealed his dependency on cocaine and claimed that marijuana helped him break free from addiction. He currently resides in Las Vegas and owns a marijuana farm in California.

 

His personal story has attracted many fans, who seem eager to support him. "He has gone through some difficult times, and I can relate to that," said 26-year-old Tony Pedroza, a boxing enthusiast from Brooklyn who was standing in line in Manhattan to see Tyson.

 

Monifa Jones-Tuck and her husband, Troy Tuck, drove from Bethlehem, Pennsylvania to show their support for him. Jones expressed that they have been following Tyson's boxing career since the beginning and admire his progress.

 

"After using marijuana, his mind is currently in a good and calm state," he said. "It suits him well, and he also looks great."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
Product | SKE Launches FRESA PRO in the U.S., Introducing Fresh Lock Technology for E-Liquid Management in High-Capacity Vapes
Product | SKE Launches FRESA PRO in the U.S., Introducing Fresh Lock Technology for E-Liquid Management in High-Capacity Vapes
Shenzhen SKE Technology has launched the FRESA PRO in the United States, a high-capacity rechargeable disposable vape featuring Fresh Lock electromagnetic valve supply control technology. The device combines a claimed capacity of up to 40,000 puffs, dual mesh coils, dual output modes and a transparent tank design. The launch reflects the high-capacity disposable vape segment’s shift from puff-count competition toward improved e-liquid management and device-level experience.
Aug.03
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11